2011-48-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-METHOXYBENZYL)HYDRAZINE DIHYDROCHLORIDE is used as a chemical intermediate for the preparation of heterocyclic derivatives that are useful as SHP2 inhibitors. SHP2 is a protein tyrosine phosphatase that plays a crucial role in various cellular signaling pathways, and its inhibition has been shown to have potential therapeutic benefits in the treatment of certain cancers and other diseases.

InChI:InChI=1/C8H12N2O.ClH/c1-11-8-4-2-7(3-5-8)6-10-9;/h2-5,10H,6,9H2,1H3;1H

Upstream product

• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1015060-08-8 4-chloro-3-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-d]pyrimidine-6-amine 
• 1160931-80-5 1-(4-methoxybenzyl)-3-cyclopropyl-1H-pyrazol-5-amine 
• 949556-61-0 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine 

Relevant academic research and scientific papers

6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE

The 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivatives or salts thereof of the present invention have BRD4 inhibitory activity, and thus, they are useful as medicaments, in particular, as prophylaxis and/or therapeutic agents for diseases associated with BRD4.

EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X, Y, R1, R2, R3a, R3b, R4a, R4b and R5 are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4A and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS

The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as inhibitors of H1R and/or H4R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF

The present invention relates to a cytokine production inhibitor comprising a compound of the formula [I] wherein R1is aryl or heteroaryl; B is a group of the formula (a) or (b) wherein R2is hydrogen atom, hydroxy, halogen atom and t

Therapeutic agent for osteoporosis and triazepine compound

Therapeutic agents for osteoporosis comprising, as an active ingredient, a triazepine compound of the formula ?I! STR1 wherein R1 is aryl or heteroaryl; R2 is hydrogen atom, hydroxy, halogen atom or lower alkyl; R4 is hydrogen atom or halogen atom, or R2 and R4 form carbonyl combinedly together with the carbon atom to which they bond; R3 is hydrogen atom, lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, --X--Y wherein X is --(CH2)m --, --CO--, --COCH2 --, --NH--, --NHCH2 --, --CH2 NH--, --CH2 NHCO--, --OCH2 --, --(CH2)n O-- or --CH2 S-- and Y is halogen atom, cycloallyl, aryl or heteroaryl; and A is benzene ring or thiophene ring, or a salt thereof, novel triazepine compounds, and intermediate triazepine compounds for producing these triazepine compounds. The triazepine compounds of the formula ?I! have superior bone resorption-inhibitory action and are useful as therapeutic agents for osteoporosis.